Primary prevention of cardiovascular disease
Garrett, R.E.
Journal of Family Practice 22(3): 222 224
1986
ISSN/ISBN: 0094-3509 PMID: 3950551 Document Number: 271432
Document emailed within 1 workday
Related Documents
Miser, W.Fred. 2011: Appropriate aspirin use for primary prevention of cardiovascular disease American Family Physician 83(12): 1380-1386García-Palmieri, M.R. 2000: Primary and secondary prevention of cardiovascular disease in the elderly Boletin de la Asociacion Medica de Puerto Rico 92(1-3): 3-8
Brohet, C. 1995: Risk factors and primary prevention of cardiovascular disease Journal de Pharmacie de Belgique 50(1): 20-24
Sobieszczańska, Młgorzata.; Kałka, D.; Pilecki, W.; Adamus, J. 2009: Physical activity in basic and primary prevention of cardiovascular disease Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 26(156): 659-664
Fretheim, A.; Bjørndal, A.; Oxman, A.D.; Dyrdal, A.; Golding, M.; Ose, L.; Reikvam, A.; Teisberg, P. 2002: Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 122(23): 2287-2288
Hovens, M.M.C.; Cannegieter, S.C. 2004: Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease Nederlands Tijdschrift Voor Geneeskunde 148(42): 2097; Author Reply 2097-8
De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Nordt, T. 2001: Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project Der Internist 42(12): 1705-1707
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25
1981: Evaluation strategy of the Swiss National Research Program on primary prevention of cardiovascular disease. Report of the Programme National Suisse de Recherche No. 1A. Groupe d'étude Revue d'Epidemiologie et de Sante Publique 29(3): 315-325
Lowe, G.; Rumley, A.; Norrie, J.; Ford, I.; Shepherd, J.; Cobbe, S.; Macfarlane, P.; Packard, C. 2000: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thrombosis and Haemostasis 84(4): 553-558
Huo, Y.; Li, X.Y. 2018: Deepen our thoughts on the prevention of cardiovascular disease and actively contribute to the earlier appearance of the turning point noting the reduced prevalence of cardiovascular diseases Zhonghua Xin Xue Guan Bing Za Zhi 46(1): 3-6
Kleinert, S. 1999: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation Lancet 354(9181): 841
Onder, L.; Nicolosi, G.Luigi. 2010: The primary role of cardiologists in cardiovascular prevention Giornale Italiano di Cardiologia 11(5 Suppl. 3): 131s-132s
Volpe, M.; Tocci, G. 2012: Global cardiovascular risk management in primary prevention Current Vascular Pharmacology 10(6): 709-711
Chazov, E.I. 2002: Problems in primary and secondary prevention of cardiovascular diseases Terapevticheskii Arkhiv 74(9): 5-8
Béliard-Lasserre, S. 2016: Should we prescribe statins for primary prevention of cardiovascular risk? Rather yes La Revue du Praticien 66(3): 332-334
Richard, J.L.; Delahaye, F. 1998: Cardiovascular prevention, primary or secondary, in high risk patients Archives des Maladies du Coeur et des Vaisseaux 91(12): 1495-1502
Schlierf, G. 1980: Primary and secondary prevention of cardiovascular diseases - metabolic aspects Verhandlungen der Deutschen Gesellschaft für Innere Medizin 86: 546-550
Tkacheva, O.N.; Sharashkina, N.V. 2010: Possibilities of ramipril in primary and secondary prevention of cardiovascular diseases Kardiologiia 50(8): 63-66